English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169289
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future

AuthorsValent, Peter; Akin, Cem; Hartmann, Karin; Nilsson, Gunnar; Reiter, Andreas; Hermine, Olivier; Sotlar, Karl; Sperr, Wolfgang R.; Escribano, Luis; George, Tracy I.; Kluin-Nelemans, Hanneke C.; Ustun, Celalettin; Triggiani, Massimo; Brockow, Knut; Gotlib, Jason; Orfao, Alberto ; Schwartz, Lawrence B.; Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten; Kovanen, Petri T.; Galli, Stephen J.; Austen, K. Frank; Arber, Daniel A.; Horny, Hans-Peter; Arock, Michel; Metcalfe, Dean D.
KeywordsMast cells
Midostaurin
Prognostication
Tryptase
KIT D816V
Mastocytosis
Issue Date2017
PublisherAmerican Association for Cancer Research
CitationCancer Research 77(6): 1261-1270 (2017)
AbstractMastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced SM.
Publisher version (URL)https://doi.org/10.1158/0008-5472.CAN-16-2234
URIhttp://hdl.handle.net/10261/169289
Identifiersdoi: 10.1158/0008-5472.CAN-16-2234
e-issn: 1538-7445
issn: 0008-5472
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
advanfutur.pdf393,09 kBAdobe PDFThumbnail
View/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.